15 completed, 5 unknown, 1 not yet recruiting, 1 terminated. 22 Phase 1, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 22 | Completed 15, Unknown 5, Not yet recruiting 1, Terminated 1 |
| Phase 2 | 9 | Completed 5, Unknown 2, Not yet recruiting 1, Terminated 1 |
Follow Coronavirus: new trials by email Literature Review of Coronavirus trials Research Report on Coronavirus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Next Generation T-cell Vaccine Against Coronavirus Disease (COVID-19) PepGNP-COVID19 (One vaccination), Water for injection (One vaccination), PepGNP-COVID19 (Two vaccinations) - Coronavirus, SARS-CoV-2 Infection | Phase 1 / Phase 2 | Not yet recruiting | Gylden Pharma Ltd | 110 | 2025-09-01 | 2025-02-24 |
| First-in-human Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Coronavirus Vaccine Candidate in Healthy Volunteers OVX033, Saline solution - Coronavirus | Phase 1 | Completed | Osivax | 48 | 2024-01-08 | 2026-09-10 |
| A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against SARS-CoV-2 LD Vehicle-GNP, LD PepGNP-Covid19, HD Vehicle-GNP - Coronavirus, SARS-CoV-2 Infection | Phase 1 | Completed | Gylden Pharma Ltd | 26 | 2022-01-10 | 2025-02-12 |
| A Study to Evaluate Safety, Tolerability, and Reactogenicity of an RBD-Fc-based Vaccine to Prevent COVID-19 Baiya SARS-CoV-2 Vax 1 - Coronavirus | Phase 1 | Completed | Baiya Phytopharm Co., Ltd. | 48 | 2021-09-11 | 2023-01-12 |
| Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2（COVID-19） Phase I Clinical Trial (3~17 Years Old) Recombinant new coronavirus vaccine (CHO cell) group, Recombinant new coronavirus vaccine (CHO cells) placebo group - Coronavirus | Phase 1 | Completed | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | 75 | 2021-07-03 | 2023-04-25 |
| COV-CHIM01: SARS-CoV-2 (COVID-19) Dose Finding Infection Study SARS-CoV-2 virus - Coronavirus | Phase 1 | Unknown | University of Oxford | 132 | 2021-05-27 | 2023-01-06 |
| A Study of Intranasal ChAdOx1 nCOV-19 ChAdOx1 nCov-19 - Coronavirus | Phase 1 | Completed | University of Oxford | 42 | 2021-04-01 | 2022-10-24 |
| Exercise Therapy in Cancer Patients Who Are Recovering From COVID-19 Aerobic Exercise Therapy - Covid19, Coronavirus | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 3 | 2021-03-29 | 2025-10-27 |
| Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS Umbilical Cord Lining Stem Cells (ULSC), Placebo (carrier control) - Covid19, Corona Virus Infection | Phase 1 / Phase 2 | Completed | Restem, LLC. | 17 | 2020-12-23 | 2024-04-09 |
| N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19) N-acetyl glucosamine (NAG), Control - Coronavirus, Covid19 | Phase 1 | Completed | Quantinosis.ai LLC | 150 | 2020-11-14 | 2023-04-04 |
| Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease With Methotrexate Associated to LDL Like Nanoparticles (Nano-COVID19) Methotrexate-LDE phase 1, Methotrexate-LDE phase 2, Placebo-LDE phase 2 - Coronavirus, Inflammation | Phase 1 / Phase 2 | Unknown | University of Sao Paulo General Hospital | 100 | 2020-10-27 | 2021-01-14 |
| Inflammatory Signal Inhibitors for COVID-19 (MATIS) Ruxolitinib, Fostamatinib, Standard of care - Coronavirus, Covid19 | Phase 1 / Phase 2 | Completed | Imperial College London | 185 | 2020-10-02 | 2025-11-18 |
| Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 CYNK-001 - Coronavirus, Coronavirus Infection | Phase 1 / Phase 2 | Terminated | Celularity Incorporated | 7 | 2020-09-02 | 2026-06-26 |
| Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2 Phase I Clinical Trial (≥60 Years Old) Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cell) low-dose group, Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) high-dose group, Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) placebo group - Coronavirus | Phase 1 | Unknown | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | 50 | 2020-08-19 | 2021-01-27 |
| COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection ChAdOx1 nCoV-19, Normal saline 0.9% - Coronavirus | Phase 1 / Phase 2 | Unknown | University of Oxford | 2130 | 2020-06-24 | 2020-11-27 |
| Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine Recombinant new coronavirus vaccine (CHO cell) low-dose group, Recombinant new coronavirus vaccine (CHO cells) high-dose group, Recombinant new coronavirus vaccine (CHO cells) placebo group - Coronavirus | Phase 1 | Unknown | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | 50 | 2020-06-22 | 2020-12-03 |
| A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19 CVnCoV Vaccine, Placebo - Severe Acute Respiratory Syndrome, Coronavirus | Phase 1 | Completed | CureVac | 280 | 2020-06-18 | 2023-01-30 |
| A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19 APL-9, Vehicle Control - COVID, Covid-19 | Phase 1 / Phase 2 | Completed | Apellis Pharmaceuticals, Inc. | 72 | 2020-05-28 | 2022-03-23 |
| Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells Allogenic pooled olfactory mucosa-derived mesenchymal stem cells, Standard treatment according to the Clinical protocols - COVID, Covid-19 | Phase 1 / Phase 2 | Completed | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | 32 | 2020-05-11 | 2021-08-23 |
| A Study of a Candidate COVID-19 Vaccine (COV001) ChAdOx1 nCoV-19, MenACWY, ChAdOx1 nCoV-19 full boost - Coronavirus | Phase 1 / Phase 2 | Completed | University of Oxford | 1077 | 2020-04-23 | 2025-09-03 |
Showing 20 of 22. Sign in to see all of them.
Coronavirus Infections (22) · COVID-19 (15) · Pneumonia (3) · Severe Acute Respiratory Syndrome (3) · Pneumonia, Viral (2) · Acute Lung Injury (1) · Coronaviridae Infections (1) · Immune System Diseases (1) · Inflammation (1) · Lung Diseases (1) · Lung Diseases, Interstitial (1) · Motor Activity (1) · Neoplasms (1) · Nidovirales Infections (1) · RNA Virus Infections (1)
Infections (22) · Coronaviridae Infections (21) · Nidovirales Infections (21) · RNA Virus Infections (21) · Virus Diseases (21) · Lung Diseases (14) · Respiratory Tract Diseases (14) · Respiratory Tract Infections (14) · Pneumonia, Viral (13) · Pneumonia (12) · Behavior (1) · Lung Injury (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Respiration Disorders (1)
ChAdOx1 nCoV-19 (3) · Population Groups (3) · Saline Solution (2) · Acetaminophen (1) · Acetylglucosamine (1) · Baiya SARS-CoV-2 VAX COVID-19 vaccine (1) · Biological Products (1) · CVnCoV COVID-19 vaccine (1) · Injections (1) · MenACWY (1) · Standard of Care (1) · Water (1) · fostamatinib (1) · molnupiravir (1) · ruxolitinib (1)
University of Oxford (4) · Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. (3) · Gylden Pharma Ltd (2) · Apellis Pharmaceuticals, Inc. (1) · Baiya Phytopharm Co., Ltd. (1) · Celularity Incorporated (1) · CureVac (1) · Imperial College London (1) · Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus (1) · Memorial Sloan Kettering Cancer Center (1) · Osivax (1) · Quantinosis.ai LLC (1) · Restem, LLC. (1) · Ridgeback Biotherapeutics, LP (1) · Ruijin Hospital (1)
United Kingdom (5) · United States (5) · China (4) · Brazil (2) · Belarus (1) · Belgium (1) · France (1) · Germany (1) · Philippines (1) · South Africa (1) · Switzerland (1) · Thailand (1)
Alberto R Edison, MD (1) · Alexander Douglas, Dr (1) · Andrei Y Hancharou, Dr. (1) · Andrew Pollard, Prof (1) · Blaise Genton, Prof. (1) · Corey Casper, MD MPH (1) · Eduard A Dotsenko, Dr., prof. (1) · Helen McShane, MD and PhD (1) · Hong Ren, master (1) · Jessica Scott, PhD (1) · Jie-ming Qu, MD.,PhD. (1) · Jim Bush, MBChB, PhD (1) · Natalia G Antonevich, Dr. (1) · Nichola Cooper (1) · Odile Launay, MD (1)
PMID 33306989, PMID 33617777, PMID 32007143, PMID 32122636, PMID 32211963, PMID 32653469, PMID 32702298, PMID 33335322, PMID 33725432, PMID 33773111, PMID 33845867, PMID 34306677, PMID 34416193, PMID 34480858, PMID 35619189, PMID 36273491, PMID 36435633, PMID 36803632, PMID 36851662, PMID 37138460, PMID 37149443, PMID 37903635, PMID 38703782, PMID 40197245, PMID 40248705, PMID 41644167, PMID 8961899